Search
for
Sort by
Research 30 of 74
- No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Low-dose oral minoxidil for androgenetic alopecia is not associated with blood pressure changes in patients also taking other antihypertensive medications: A multi-center cohort study using TriNetX
- 76976 Association of Depression with Finasteride Stratified by Dosage and Diagnosis: A Retrospective Cohort Study Using the TriNetX Database
- The Association Between 5α-Reductase Inhibitors and the Presence of Subsequent Dry Eye Disease in Androgenetic Alopecia: A TriNetX Database Study
- No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study
- Nonscarring Alopecia in Adults Treated With GLP ‐1s: A Propensity Score Matched TriNetX Cohort Study
- 0414 Cumulative atopic disease burden is associated with increased risk of alopecia areata: A TriNetX cohort study
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Broad laboratory testing does not show utility for telogen effluvium: a retrospective analysis of 22-million laboratory results using TriNetX
- Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study
- Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
- When hair dig into the brain, JAKi , may help!
- The Risk of Benign Prostatic Hyperplasia and Prostate Cancer With Long-Term, Low Dose Finasteride Use in Adult Men with Nonscarring Alopecia: A Propensity-Matched Observational Study
- 0250 Systemic therapy associates with a lower incidence of male infertility among psoriasis patients
- 53028 Semaglutide and Hair Loss: A Real-World Analysis
- LB892 Assessing the risk of alopecia areata development in patients with seasonal and food allergies: a matched population-level analysis
- Low serum testosterone is associated with an increased risk of first-time renal calculi in men without testosterone replacement therapy
- Simultaneous Versus Delayed Initiation of Spironolactone and Low‐Dose Oral Minoxidil: Adverse Event Rates in a Retrospective Cohort Study
- 0282 Effect of systemic immunomodulators on incidence of alopecia areata: A retrospective cohort study
- LB923 A matched cohort study evaluating the risk of keloid development in alopecia areata patients
- Burden of Eosinophilic Esophagitis and Gastroesophageal Reflux Disease in Metabolic Dysfunction–Associated Steatotic Liver Disease: A Comprehensive US Healthcare Analysis
- 0441 Systemic autoimmune comorbidity in alopecia totalis and universalis compared with patchy alopecia areata: A retrospective cohort study
- 76708 Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization
- Association of Janus kinase inhibitors with reduced depression in alopecia areata